Kisun Pharm Successfully Renews Bid for Imatinib Mesylate Tablets in National Volume-Based Procurement (VBP)-Kisun Pharmaceutical-Drug products,Healthcare Services

Home page

Kisun Pharm Successfully Renews Bid for Imatinib Mesylate Tablets in National Volume-Based Procurement (VBP)

2026-02-11

FONT

On February 10, 2026, during the public announcement of selection results for products whose agreements under the National Organization for Centralized Drug Procurement had expired, Imatinib Mesylate Tablets (Trade name: Qiaoning) — a core anti-tumor product manufactured by Zhejiang Kisun Pharmaceutical Co., Ltd. — successfully secured a preliminary selection slot. This achievement is attributed to the product's excellent quality standards and the company's robust market supply capabilities.

Core Highlights: Continued Dedication to Quality and Responsibility

Quality First, International Standards: Our Imatinib Mesylate Tablets are produced in strict accordance with the consistency evaluation standards for the quality and efficacy of generic drugs. They demonstrate high consistency with the original drug in terms of bioequivalence and clinical efficacy.
Benefiting Livelihoods, Reducing Burden: As a first-line treatment for Chronic Myeloid Leukemia (CML) and Gastrointestinal Stromal Tumors (GIST), the continued selection of this product will significantly lower long-term medication costs for patients and alleviate financial pressure on families.
Supply Guarantee, Empowering Terminals: Kisun Pharm possesses advanced production lines and a rigorous supply chain management system. This ensures a stable and high-quality supply of medicine to medical institutions at all levels throughout the agreement period.

Looking Forward: Prioritizing Innovation and Accessibility This preliminary selection marks a milestone in Kisun Pharm’s long-term cultivation of the chronic disease and oncology sectors. Guided by our vision of "Striving to Become a Globally Competitive Specialty Pharmaceutical Enterprise" Kisun Pharm will continue to increase R&D investment and expand our product portfolio.

Keywords:

None

Zhejiang Kisun Pharmaceutical’s Imatinib Tablets Successfully Shipped to Europe for the First Time

None

Zhejiang Kisun Pharmaceutical’s Imatinib Tablets Successfully Shipped to Europe for the First Time

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.